Effect of Data Quality and Data Quantity on the Estimation of Intrinsic Solubility: Analysis Based on a Single-Source Data Set

Effect of Data Quality and Data Quantity on the Estimation of Intrinsic Solubility: Analysis Based on a Single-Source Data Set

Publication: Mol Pharm
Software: ADMET Predictor®
Division: Cheminformatics

Aqueous solubility is one of the most important physicochemical properties of drug molecules and a major driving force for oral drug absorption.

Phase I Clinical Trial of NH130 and the Prediction of its Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling

Phase I Clinical Trial of NH130 and the Prediction of its Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling

Authors: Zhang K, Zhao S, Du J, Zhang L
Publication: Front Pharmacol
Software: GastroPlus®
Division: PBPK

Parkinson’s disease psychosis (PDP) is a common and distressing complication of Parkinson’s disease (PD), characterized by hallucinations and delusions.

CFD-PK model for nasal suspension sprays: Validation with human adult in vivo data for triamcinolone acetonide

CFD-PK model for nasal suspension sprays: Validation with human adult in vivo data for triamcinolone acetonide

Publication: Intl J Pharm
Software: GastroPlus®
Division: PBPK

The objectives of this study were to expand and implement a Computational Fluid Dynamics (CFD)-Dissolution, Absorption and Clearance (DAC)-Pharmacokinetics (PK) multi-physics modeling framework for simulating the transport of suspension-based nasal corticosteroid sprays.

Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity

Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity

Authors: Li X, Liu S, Liu D, Yu M, Wu X, Wang H
Publication: Clin Pharmacokinet
Software: GastroPlus®
Division: PBPK

In recent years, virtual drug study, as an emerging research strategy, has become increasingly important in guiding and promoting new drug research and development.

PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management

PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management

Publication: Pharmaceutics
Software: GastroPlus®
Division: PBPK

This study aimed to model the pharmacokinetics of lamotrigine (LTG) and efavirenz (EFV) in pregnant women using physiologically based pharmacokinetic (PBPK) and pregnancy-specific PBPK (p-PBPK) models.

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

Publication: CPT Pharmacometrics Syst Pharmacol
Software: GastroPlus®
Division: PBPK

Omaveloxolone is a nuclear factor (erythroid-derived 2)-like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg orally once daily on an empty stomach.

A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation

A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation

Publication: AAPS PharmSciTech
Software: GastroPlus®
Division: PBPK

Physiologically based pharmacokinetic (PBPK) or physiologically based biopharmaceutics models (PBBM) demonstrated plethora of applications in both new drugs and generic product development.

Novel omeprazole delayed release orally disintegrating tablets for enhanced patient compliance: a case of model informed formulation development

Novel omeprazole delayed release orally disintegrating tablets for enhanced patient compliance: a case of model informed formulation development

Publication: Xenobiotica
Software: GastroPlus®
Division: PBPK

The advanced in silico simulation tools, such as physiologically based biopharmaceutics models (PBBM) or physiologically based pharmacokinetic models (PBPK), play critical role in model informed formulation development.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Publication: J Med Chem
Software: GastroPlus®
Division: PBPK

Various small molecule GLP1R agonists have been developed and tested for treating type 2 diabetes (T2DM) and obesity.

Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach

Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach

Publication: Toxicol Appl Pharmacol
Software: DILIsym®

Propylthiouracil (PTU) and methimazole (MMI), two classical antithyroid agents possess risk of drug-induced liver injury (DILI) with unknown mechanism of action.

Redefining Statin Dosage Post-Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach

Redefining Statin Dosage Post-Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach

Publication: Journal of Clinical Pharmacology
Software: Monolix®

Roux-en-Y gastric bypass (RYGB) involves creating a small stomach pouch, bypassing part of the small intestine, and rerouting the digestive tract.

Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation

Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation

Publication: Curr Res Pharmacol Drug Discov
Software: Monolix®

LNA-i-miR-221 is a novel microRNA(miRNA)-221 inhibitor designed for the treatment of human malignancies.

Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis

Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis

Publication: Scientific Reports
Software: GastroPlus®
Division: PBPK

Bacterial vaginosis (BV), primarily attributed to Gardnerella vaginalis, poses significant challenges due to antibiotic resistance and suboptimal treatment outcomes.

Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population

Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population

Publication: Clin Pharmacokinet
Software: GastroPlus®
Division: PBPK

Endometriosis, a common and distressing gynecological condition, affects fertility and causes pain, is often managed with medications such as Elagolix.

Cellulose ether and carbopol 971 based gastroretentive controlled release formulation design, optimization and physiologically based pharmacokinetic modeling of ondansetron hydrochloride minitablets

Cellulose ether and carbopol 971 based gastroretentive controlled release formulation design, optimization and physiologically based pharmacokinetic modeling of ondansetron hydrochloride minitablets

Publication: Int J Biol Macromol
Software: GastroPlus®
Division: PBPK

This study aims to design and optimize ondansetron (OND) gastro-retentive floating minitablets for better and prolonged control of postoperative nausea and vomiting (PONV) with improved patient compliance.